Recombinant Human EPO
EPO is predominantly synthesized and secreted by tubular and juxtatubular capillary, endothelial, and interstitial cells of the kidney. Approximately 10-15% of the total amount of Epo comes from extrarenal sources and is predominantly produced by hepatocytes and Kupffer cells of the liver. Approximately 40% of the molecular mass of Epo is due to its glycosylation. Glycosylation is an important factor determining the pharmacokinetic behavior of Epo in vivo. Non-glycosylated Epo has an extremely short biological half life. It still binds to its receptor and may even have a higher specific activity in vitro.
Product Specifications
CAS Number
9000-83-3
Gene Name
EPO
Gene Aliases
Erythropoietin<br/>Recombinant Human Erythropoietin-Alpha (EPO)
Gene ID
2056
Accession Number
P01588
Organism
Human
Source
CHO
Concentration
<1.0 EU/μg of recombinant protein as determined by the LAL method.
Purity
>95% as determined by SDS-PAGE
Solubility
Function
Molecular Weight
20
Shipping Conditions
Ambient Temperature
Storage Conditions
Appearance
Lyophilized Powder
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS (pH 7)
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
SAAL1, CT (SAAL1, Protein SAAL1) (MaxLight 405)
SAAL1, CT (SAAL1, Protein SAAL1) (MaxLight 405)